University of Cincinnati

David Plas

Jarek Meller

Julio Alberto Landero Figueroa

Shuchi Gulati

Catherine Behrmann

Bhargav Vemuri

Maria Franciszka Czyzyk-Krzeska

John Thomas Cunningham, Iv

A method of diagnosing the likelihood of recurrence of clear cell renal cell carcinoma is provided. The method involves a) detecting the gene expression signatures of mitochondrial electron transport chain subunits, mitochondrial ribosomal proteins, major histocompatibility complex class II (MHC-II) proteins or combinations thereof in a kidney tumor tissue sample; and b) determining that the subject has an elevated risk of recurrence of clear cell renal cell carcinoma if the gene expression signatures include certain sequences. In another embodiment, the method uses copper levels to diagnose the likelihood of recurrence of clear cell renal cell carcinoma.

Diagnostic tools and treatments for clear cell renal cell carcinoma

Methods for targeting adaptive responses to chemotherapy are described. In various embodiments, a method comprises administering at least one compound that inhibits S6K1, mTORC1 or upstream or downstream pathway components of S6K1 or mTORC1, in association with administration of at least one inhibitor of PPAR&#x3b1;, PPAR&#x3b4;, or PGC1&#x3b1;. In various embodiments, the compound that inhibits S6K1, mTORC1, or upstream or downstream pathway components of S6K1 or mTORC1 is rapamycin, everolimus, temsirolimus, or imatinib. The inhibitor of PPAR&#x3b1;, PPAR&#x3b4;, or PGC1&#x3b1; can be an antagonist or an inverse agonist selected from GW6471, GSK3787, GSK0660, and ST247.

Targeting metabolic adaptive responses to chemotherapy

Growing community of inventors

Cincinnati, OH, United States of America

David Plas